ETHORICOXIB IN THE TREATMENT OF RHEUMATIC DISEASES
Ethoricoxib is a new-generation selective COX-2 inhibitor. It has been recently licensed in Russia for the treatment of osteoarthrosis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), and acute gouty arthritis. The drug is supplied as 60-, 90-, and 120-mg tablets. It is given once daily...
Main Author: | Yu A Olyunin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2010-03-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/277 |
Similar Items
-
ETORICOXIB IS A NEW SELECTIVE CYCLOOXYGENASE-2 INHIBITOR
by: A E Karateev
Published: (2009-06-01) -
ETORICOXIB IS A NEW SELECTIVE CYCLOOXYGENASE-2 INHIBITOR
by: A E Karateev
Published: (2009-06-01) -
Temporomandibular joint dysfunction in various rheumatic diseases
by: F.J. Aceves-Avila, et al.
Published: (2013-07-01) -
Radiculopathy in a patient with chronic tophaceus gout: vertebral imaging
by: Joana Borges, et al.
Published: (2017-07-01) -
CONSERVATIVE ORTHOPEDIC TREATMENT OF RHEUMATIC DISEASES: RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, OSTEOARTHROSIS, SOFT TISSUE DISEASES (PART II)
by: V P Pavlov
Published: (2009-06-01)